Pioneering FDG PET at the University of Pennsylvania
Abass Alavi and collaborators performed some of the first human studies using 18F fluorodeoxyglucose FDG in the mid 1970s and these early whole body and brain studies demonstrated that FDG PET could map glucose metabolism in vivo and provide clinically relevant information about tumor activity and brain function
Clinical Translation and Impact
The introduction of FDG as a broadly useful tracer transformed PET from a research tool into a clinical modality for oncology staging therapy response and for neurologic and cardiac applications and FDG PET became a cornerstone of molecular imaging because it provided a sensitive measure of metabolic activity
Standardization and Multicenter Adoption
Following early demonstrations teams worked to standardize injection protocols uptake times and reconstruction parameters and multicenter validation and improvements in cyclotron and radiochemistry infrastructure enabled wider clinical adoption and integration with CT for combined anatomic and metabolic imaging